In clinical studies, the ETAR inhibitor atrasentan successfully decreased PSA in male patients with hormone-refractory disease185 and markers of bone turnover in prostate cancer patients with bone metastases.441. This evidence concerns the gene KLK3 and prostate carcinoma.